Generating CD8+ T cell antitumor responses is the major goal of most cancer immunotherapies because it is considered that CD8+ T cells not only provide effective immediate cytotoxicity against tumor cells, but also generate immunological memory to sustain anti-tumor immunity. The gene discussed is CD8A; the disease is cancer.